PriceTargets.com logo

MindWalk - HYFT Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.00 As of 01/15/2026 05:00 PM ET
▼ -0.14 (-6.54%)

This chart shows the closing price for HYFT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MindWalk Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HYFT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HYFT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for MindWalk in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.00.

This chart shows the closing price for HYFT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 2 investment analysts is to sell stock in MindWalk.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/19/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/16/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
1/15/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/14/2026Weiss RatingsInitiated CoverageSell (D-)
1/12/2026Zacks ResearchDowngradeHold ➝ Strong Sell
(Data available from 1/15/2021 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/19/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/19/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/17/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/17/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/16/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/16/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/15/2026

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Read More

Today's Range

Now: $2.00
Low: $1.95
High: $2.21

50 Day Range

MA: N/A

52 Week Range

Now: $2.00
Low: $0.27
High: $3.25

Volume

710,882 shs

Average Volume

563,926 shs

Market Capitalization

$92.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of MindWalk?

The following equities research analysts have issued reports on MindWalk in the last twelve months: Weiss Ratings, and Zacks Research.
View the latest analyst ratings for HYFT.

What is the current price target for MindWalk?

0 Wall Street analysts have set twelve-month price targets for MindWalk in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for MindWalk in the next year.
View the latest price targets for HYFT.

What is the current consensus analyst rating for MindWalk?

MindWalk currently has 2 sell ratings from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe HYFT will underperform the market and that investors should sell shares of MindWalk.
View the latest ratings for HYFT.

What other companies compete with MindWalk?

Other companies that are similar to MindWalk include 4D pharma, Ainos, Aktis Oncology, Alvotech and Aravive. Learn More about companies similar to MindWalk.

How do I contact MindWalk's investor relations team?

MindWalk's physical mailing address is 880 - 580 HORNBY STREET, VANCOUVER, British Columbia, Canada, V6C3B6. The company's listed phone number is (604) 806-0626. The official website for MindWalk is ipatherapeutics.com. Learn More about contacing MindWalk investor relations.